title: Hepatic arterial infusion chemotherapy combined with endogenetic hyperthermia treatment of hilar cholangiocarcinoma.
abstract: OBJECTIVE
  To evaluate the curative effect and clinical application of hepatic arterial infusion (HAI) chemotherapy combined with endogenetic field tumor hyperthermia (EFTH) in patients with hilar cholangiocarcinoma.
  
  
  METHODS
  Nine patients with unresectable hilar cholangiocarcinoma were enrolled. They were first treated with HAI using gemcitabine, and then carboplatin was continuously infused intra-arterially whereas EFTH was applied to the hilar region for 60 min. After hyperthermia, 5-fluorouracil was administered intra-arterially for three days. The same dose of gemcitabine was administered intravenously on Day 8. The side effects, tumor markers, tumor response and overall survival (OS) were observed and assessed.
  
  
  RESULTS
  Nine patients underwent 27 cycles of the combination therapy. Of the nine patients, five patients achieved complete remission and they are still alive, and four died. Of the four patients who died, two achieved partial remission, one had stable disease, and one had progressive disease. The tumor markers decreased at varied degrees among the seven patients. The overall response rate was 77.78% (7/9), and the disease control rate was 88.89% (8/9). The treatment had no severe side effects and complications, including grade 3/4 hematological toxicities.
  
  
  CONCLUSIONS
  HAI chemotherapy combined with EFTH is safe, minimally invasive, and well tolerated.
authors.forename: Yao-Ting
authors.initials: YT
authors.lastname: Chen
authors.forename: He-Rui
authors.initials: HR
authors.lastname: Yao
authors.forename: Lin-Feng
authors.initials: LF
authors.lastname: Xu
authors.forename: Hong-Liang
authors.initials: HL
authors.lastname: Sun
authors.forename: Hong
authors.initials: H
authors.lastname: Teng
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001650:Bile Duct Neoplasms / Q000628:therapy*; D014408:Biomarkers, Tumor / Q000032:analysis; D016190:Carboplatin / Q000627:therapeutic use; D018281:Cholangiocarcinoma / Q000628:therapy*; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D003952:Diagnostic Imaging; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006499:Hepatic Artery; D006801:Humans; D007036:Hypothermia, Induced / Q000379:methods*; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D003841:Deoxycytidine; D016190:Carboplatin; D005472:Fluorouracil; D000093542:Gemcitabine